SCHEMBL2865387

SCHEMBL2865387

Nc1c2c(=O)[nH]c3ccccc3c2nn1-c1cccc(C(=O)O)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 1/20 0.46
LMNA P02545 1/20 0.46
ADORA3 P0DMS8 3/20 0.44
ABL1 P00519 1/20 0.43
LCK P06239 1/20 0.43
FYN P06241 1/20 0.43
LYN P07948 1/20 0.43
SRC P12931 1/20 0.43
MAPK14 Q16539 1/20 0.43
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
PARP1 P09874 1/20 0.41
MEN1 O00255 2/20 0.40
MAPT P10636 2/20 0.40
KMT2A Q03164 2/20 0.40
PMM2 O15305 1/20 0.40
IDE P14735 1/20 0.40
MPI P34949 1/20 0.40
PHOSPHO1 Q8TCT1 1/20 0.40
APOBEC3G Q9HC16 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2866823 0.88 MEN1 (0.46) TDP2ADORA3PARP1MEN1KMT2A
SCHEMBL2861092 0.86 ADORA3 (0.53) TDP2ADORA3ABL1LCKFYN
SCHEMBL2878474 0.85 TDP2 (0.49) TDP2ADORA3ABL1LCKFYN
SCHEMBL2859052 0.85 TDP2 (0.45) TDP2ADORA3ABL1LCKFYN
SCHEMBL2864776 0.83 TDP2 (0.45) TDP2LMNAADORA3ABL1LCK
SCHEMBL2868721 0.83 ADORA3 (0.45) TDP2ADORA3ABL1LCKFYN
SCHEMBL2863178 0.83 ADORA3 (0.57) TDP2LMNAADORA3ABL1LCK
SCHEMBL2871556 0.83 TDP2 (0.45) TDP2LMNAADORA3ABL1LCK
SCHEMBL2862967 0.81 ADORA3 (0.58) LMNAADORA3MEN1MAPTKMT2A
SCHEMBL2862311 0.80 KMT2A (0.52) TDP2LMNAADORA3ABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 TDP2 3548/4885LMNA 4123/4885ADORA3 1829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.